BIXT
Bioxytran, Inc.·Healthcare
0.04
3.158%(−0.00)
Market ClosedLast Updated: — ET
52W L: $0.0352W H: $0.20
BIXT NEWS
defenseworld.net
Mar 25
Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest
Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 300 shares, a decrease of 97.1% from the February 26th total of 10,300 shares. Based on an average trading volume of 1,769,827 shares, the
globenewswire.com
Mar 20
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the Company issued an aggregate of approximately 21,071,667 shares of its common stock at a purchase price of approximately $0.055 per share.
globenewswire.com
Mar 4
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and provided an update on the Company's planned Phase 3 registrational trial. The data, released March 2, 2026, were designed to establish the optimal dosing strategy and support advancement into a pivotal study intended to enable full regulatory approval.
accessnewswire.com
Mar 2
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2. The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile.
globenewswire.com
Feb 11
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001).
defenseworld.net
Feb 11
Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update
Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 5,695 shares, an increase of 1,798.3% from the January 15th total of 300 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading
